Products
MedNova: source-traced IND gap assessment.
MedNova is Amia’s regulatory AI product. It reads an IND package against guidance and flags missing, inconsistent and unsupported content before submission, for expert review.
What MedNova does
A second reader that shows its evidence.
- Deterministic checks. A rules engine applies checks that are repeatable, kept separate from AI reasoning.
- Severity-ranked findings. Critical, major and minor findings, each with the evidence and source attached.
- Source tracing. Findings link back to the passage in your documents or the public source.
- Expert review. In Amia service engagements, a regulatory expert reviews findings before they reach you.
- Deployment options. Deployment in your own cloud environment or on premise can be arranged.
Case study
MedNova IND gap assessment
How the product is used with biotech teams, and what one CEO reported.
ReadInsight
What an IND gap assessment catches
Why a second reader with a fixed rule set is worth running before you file.
ReadMedNova supports regulatory work and is not a substitute for regulatory review. It does not guarantee regulatory approval.
Start a conversation
Want to see MedNova on a sample IND?
We run guided demonstrations with demo data. Tell us about your program and timeline.